Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.
Shanghai Junshi Biosciences has announced the acceptance of their supplemental new drug application for toripalimab as a first-line treatment for melanoma in China, addressing a critical need for advanced melanoma therapies. The MELATORCH clinical study evidences toripalimab’s efficacy in prolonging progression-free survival compared to traditional chemotherapy. Toripalimab, a domestic anti-PD-1 monoclonal antibody, has already received recognition and inclusion in China’s National Reimbursement Drug List for multiple indications.
For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.
